PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO COMPLETE IF KNOWN Application Number 10/404512 6502 Confirmation Number INFORMATION DISCLOSURE Filing Date April 1, 2003 STATEMENT BY APPLICANT First Named Inventor Chen et al. (use as many sheets as necessary) Group Art Unit 1616 **Examiner Name** Attorney Docket Number 9188& 1 of 5

U. S. PATENT DOCUMENTS

EXAMINER INTIALS	Cite No.'	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
<u> </u>		US-			
	1				

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.'	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columna, Lines Where Relevant Passages or Relevant Figures Appear	۳°
SHS		EP 0,508,701B1	10-14-1992	Quest International B.V.		
		EP 0,862,863B1	.09-09-1998	Societe Des Products Nestle S.A.	·	
		EP 1,312,667A1	05-21-03	Wakamoto Pharmaceutical Co., LTD		
		W0 00/41707A1	07-20-2000	Enterprise Ireland		
		W0 00/42168A2	07-20-2000	Enterprise Ireland		
		W0 02/083879A2	10-24-2002	Alimentary Health LTD.		
		W0 03/010297A1	02-06-2003	Alimentary Health LTD.		
		W0 03/010298A1	02-06-2003	Alimentary Health LTD.		
		W0 03/010299A1	02-06-2003	Alimentary Health LTD.		
V						
EXAMINER	1			DATE CONSIDERED		·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any ments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, hington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Application Number	10/404512		
Confirmation Number	6502		
Filing Date	April 1, 2003		
First Named Inventor	Chen et al.		
Group Art Unit	1616		
Examiner Name			
Attorney Docket Number	9188&		

COMPLETE IF KNOWN

EET 2 of 5

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cita No.	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
		AGA, Abstracts, Gastroenterology Vol. 110 No. 4	↓		
		LIENDY L DINDED M.D. "Conce. Restorie and T Colle: Ingradients for Inflammatory Rowel Disease"	1.		
		Selected Cummarice, Castroenterology 1998; 115: 1695-1690, Vol. 115, No. 6	L		
		I Commence The Property of the	1		
		Medicino, National Food Biotechnology Centre, University College Cork & Dept. Surgery, Mercy Hospital, Cork ireiand			
		O'HALLORAN ET AL., "Adhesion of Potential Probiotic Basteria to Human Epithelial Cell Lines",			
•	•	Departments of Microbiology and Medicine, University College, Mercy Hospita. Cont., Ireland, Dept. of	l		
		Departments of Microbiology and Medicale, Claretony Congress, March			
		Surgery, Mercy Hospita, Sork, Ircland STALLMACH ET AL., "Induction and Modulation of Gastrointestinal Inflammation", Trends Immunology			
SHS		STALLMACH ET AL., INDUCTION BID MODULATION OF GENERAL MINISTRACTION OF THE STATE OF	1		
		Today, October 1998, Vol. 19 No. 10 pages 438-441 MARTEAU ET AL., "Potential of Using Lactic Acid Bacteria for Therapy and Immunomodulation in Man",	1		
i i		MARIEAU ET AL., "Potential of Using Lactic Actu Bacteria lot Therapy and Intrindictional Control of the Control			
		FEMS Microbiology Reviews 12 (1993) 207-220	1-		
		FERGUS SHANAHAN, "The Intestinal Immune System", Physiology of the Gastrointestinal Tract, Third			
Y		Edition, 1994	╅─		
		'VITTORIO SCARDOVI, "Irregular Nonsporing Gram-Positive Rods", Genus Rifidobacterium Orla-Jensen	1		
		1924, 472	┪—		
		SCHMITT ET AL., "The Immunostimulatory Function of IL-12 in T-Helper Cell Development and Its	1		
SHS		Regulation by TGF-B, IFN-y and IL-4",Chem Immunet Basel Karger, 1997, Vol. 68, pp 70-85	+-		
		PANWALA ET AL., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug			
		Resistance Gene, mdrla, Spontaneously Develop Colitis", The American Association of Immunologists, 1998, The Journal of Immunology, 1998 161: 5733-5744	1		
		O'MAHONY ET AL., "Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10	1		
		Knockout Mice", Aliment Pharmacol Ther 2001: 15: 1219-1225	1		
		MEDAGLINI ET AL., "Mucosal and Systemic Immune Responses to a Recombinant Protein Expressed on	T		
		the Surface of the Oral Commensal Bacterium Streptococcus gordonii after oral colonization", Proc. Natl.	1		
W		the Surface of the Oral Commensal Bacterium Streptococcus gordonii aner oral colonization, r roc. rvaii.			
		Acad. Sci. USA Vol. 92, pp 6868-6872, July 1995 Medical Sciences			
		MCCPACKEN ET AL., "Probiotice and the Immune System"	1-		
		MCBBEARTY FT AL. "Problotic Bifidobacteria and Their Identification Using Molecular Genetic	1		
		Techniques". Teagasc. Dairy Products Research Centre, Moorepark, Fermoy, Co. Cork, Ireland	1		
		Department of Microbiology, University College Cork, Ireland	ц		
EXAMINE	3	DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

opplicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

upless it contains a valid OMB control num ork Reduction Act of 1995, no persons are required to respond Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Dinder the Par

SHEET

3 of 5

(use as many sheets as necessary)

	ETE IF KNOWN
Application Number	10/404512
Confirmation Number	6502
Filing Date	April 1, 2003
First Named Inventor	Chen et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	9188&

NON PATENT LITERATURE DOCUMENTS

EXAMIN CIT ER No INITIALS*	symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	O'MAHONY ET AL., "Problotic Bacteria and Pathogenic Bacteria Elicit Differential Sytokine Responses From Dendritic Celis", XP-001097979		
SHS	CHARTERIS ET AL., "Antiobiotic Sysceptibility of Potentially Probiotic Bifidobacterium Isolates From the Human Gastrointestinal Tract", Letters in Applied Microbiology 1998, 26, 333-337		
B115	MCGEE ET AL., "A Synergistic Relationship Between TNF-x, IL-1B, and TGF-B1 on IL-6 Secretion by the IEC-6 Intestinal Epithelial Cell Line", Immunology 1995 86 6-11		
	BOUHNIK ET AL., "Effects of Bifidobacterium SP Fermented Milk Ingested With or Without Inulin on Colonic Bifidobacteria and Enezymatic activities in Healthy Humans" European Journal of Clinical Nutrition (1996) 50, 269-273		
	CHARTERIS ET AL., "Development and application of an In Vitro Methodology to Determine the Transit Tolerance of Potentially Probiotic Lactobacillus and Bifidobacterium Species in the Upper Human Gastrointestinal Tract" Journal of Applied Microbiology 1998, 84, 759-768 – XP 000929203		
	CHARTERIS ET AL., "Antiobiotic Susceptibility of Potentially Probiotic Bifidobacterium Isolates from the Human Gastrointestinal Tract, "Letters of Applied Microbiology 1998, 26, 333-337		
	CHARTERIS ET AL., "Selective Detection, Enumeration and Identification of Potentially Probiotic Lactobacillus and Bifidobacterium Species in Mixed Bacterial Populations", International Journal of Food Microbiology 35 (1997) 1-27		
	CHEVALIER ET AL., "Detection of Bifidobacterium Species by Enzymatic Methods", Journal of Applied Basteriology 1990, 68, 619-624		
V	COLLINS ET AL., "Selection of Probiotic Strains for Human Applications", In. Dairy Journal 8 (1998) 487-		
	DUNNE ET AL., "Problotics: From Myth to Reality: Demonstration of Functionality in Animal Models of Desease and in Human Clinical Trials" XP-000929178		
SHS	GIBSON ET AL., "Dietary Modulation of the Human Gut Microflora Using Prebiotics", Journal of Nutrition (1998) 80. Suppl. 2 S209-S212		
\forall	CHARTERIS ET AL., "Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-Tolerant Lactobacillus and Bifidobacterium Isolates", Journal of Food Protection Vol. 63, No. 10, 2000, pages 1369-1376		
	ARALET AL., "Cytokines: Coordinates of Immuno and Inflammatory Responses", Annu. Rov. Biochen. 90, 59; 782-826		
SHS	GROUX ET AL., "Regulatory T Cells and Inflammatory Bowel Disease", Viewpoint Immunology Today October 1999		
EXAMINER	DATE CONSIDERED	· · · ·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in informance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

COMPL	ETE IF KNOWN	
Application Number	10/404512	
Confirmation Number	6502	
Filing Date	April 1, 2003	
First Named Inventor	Chen et al.	
Group Art Unit	1616	
Examiner Name		
Attorney Docket Number	9188&	

SHEET 4 of 5

NON PATENT LITERATURE DOCUMENTS

EXAMIN ER INITIALS*	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	۴
		ARANDA ET AL., "Analysis of Intestinal Lymphocytes in Meuse Colitis Medicated by Transfer of 094+, CD45RB high I Cells to SCID Recipients", 1997, The American Association of Immunologists	
SHS		BRANDTZAEG ET AL., "Immunopathology of Human Inflammatory Bowel Disease", Springer Seminars in Immunopathology (1997) 18: 555-589	
1		CHAUVIERE ET AL., "Adhension of Human Lactobacillus Acidophilus Strain LB to Human Enterocyte-like Caco-2 Cells, Journal of General Microbiology (1992), 138, 1689-1696	
		CICCO ET AL., "Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Cology-Stimulating Factor and Tumor Necrosis Factor-Alpha", 1990 The American Society of Hematology, Blood, Vol. 75, No. 10 (May 15) 1990: pp 2049-2052	
		DONNELLY ET AL., "Differential Regulation of II-1 Production in Human Monocytes By IFN-y and IL-4", The Journal of Immunology, Vol. 145, 569-575. No. 2 July 15, 1990	
		FAVIER ET AL., Fecal B-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease", Digestive Diseases and Sciences, Vol. 42, No. 4 (April 1997), pp. 817-822	
		MONTELEONE ET AL., "Manipulation of Cytokines in the Management of Patients With Inflammatory Bowel Disease", Ann Med. 2000 Nov;32(8):552-60	
		ROGLER ET AL., "Cytokines in Inflammatory Bowel Disease", World J Surg (1998) 22:382-9]
V		STROBER ET AL., "Reciprocal IFN-gamma and TGF-Beta Responses Regulate the Occurrence of Mucosal Inflammation", Immunol Today. 1997 Feb;18(2):61-4	
		BARBARA G. ET AL., A Hole for initamination in irritable Bower Syndrome, Gut 51:41-44	T
SHS		CHADWICK ET AL." Activation of the Mucosal Immune System in Irritable Bowel Syndrome", Gastroenterology (2002) 122:1778-83	
V		ANAND ET AL." Cytokines and Inflammatory Bowel Disease", Tropical Gastroenterology. 1999; 20(3):97-106	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

SHEET 5 of 5

COMPL	ETE IF KNOWN	
Application Number	10/404512	
Confirmation Number	6502	
Filing Date	April 1, 2003	
First Named Inventor	Chen et al.	
Group Art Unit	1616	
Examiner Name		
Attorney Docket Number	9188&	

NON PATENT LITERATURE DOCUMENTS

EXAMIN ER INITIALS*	No.1 symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
		GBOLIX FT AL. "Regulatory T Cells and Inflammatory Bowel Disease". Viewpoint Immunology Today.		
SHS		GASCHE ET AL., "IL-10 Secretion and Sensitivity in Normal Human Intestine and Inflammatory Bowel Disease", Journal of Clinical Immunology Vol. 20, No. 5, 2000		
1		HOMMES ET AL., "Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease", 2000 Lippincott Williams and Wilkins 1363-1950		
		MCKAY ET AL., "Review article: In Vitro Models in Inflammatory Bowel Disease", Aliment Pharmacol Ther 1997: 11 (Suppl. 3): 70-80		
		L. LAKATOS, "Immunology of Inflammatory Bowel Diseases", Acta Physiologica Hungarica, Vol. 87 (4), pp. 355-372 (2000)		
		POWRIE ET AL., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells, Immunity Vol. 1, 553-562, October, 1994		
V		VAN DAMME ET AL., "The Proportion of Th1 Cells, Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome", Clin Exp Immunol 2001: 125:383-390		
EXAMIN	ER Shi	ulamith H. Shafer CONSIDERED 08/07/2006		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

a to a concencia of information amona	it contains a valid OMB control number	
COMPLETE IF KNOWN		
Application Number	10/810,358	
Confirmation Number	1244	
Filing Date	March 26, 2004	
First Named Inventor	Chen et al.	
Group Art Unit	1616	
Examiner Name		
Attorney Docket Number	9188R&	
	COMPL Application Number Confirmation Number Filing Date First Named Inventor Group Art Unit Examiner Name	

Wernaugh U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
SHS	1	US-5,853,697	12/29/1998	The United State Of America	
		US-			
	_	US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T°
SHS	2	W0 94/04180A2		03/03/1994	Schering Corp.		
SHS	3	W0 94/04180A3		03/03/1994	Schering Corp.		
							L
					I		
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	Application Number	10/810,358	
INFORMATION DISCLOSURE	Confirmation Number	1244	
STATEMENT BY APPLICANT	Filing Date	March 26, 2004	
(use as many sheets as necessary)	First Named Inventor	Chen et al.	
	Group Art Unit	1616	
	Examiner Name		
SHEET 2 of 2	Attorney Docket Number	9188R&	

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
SHS	XP002296946 abstract		
	5	ANDUS ET AL., "Imbalance Of The Interleukin 1 System In Colonic Mucosa – Association With Intestinal Inflammation And Interleukin 1 Receptor Agonist Genotype 2", Gut, Vol. 41, 1997, pages 651-657, page 654, column 2-page 655, column 1 figure 2D, XP002296947	
	6	ROGLER ET AL., "Cytokines In Inflammatory Bowel Disease", World Journal of Surgery, Vol. 22, 1998, pages 382-389, XP002296948 the whole document	
	7	O'CALLAGHAN ET AL., "Human Cytokine Production By Mesenteric Lymph Node Cells In Response To Probiotic And Pathogenic Bacteria", <u>Gastroenterology</u> , Vol. 122, No. 4 Suppl. 1, page A-151 DDW Meeting Abstract Nr. S1040, April 2002, XP009036734 the whole document	
\bigvee	8	MCCARTHY ET AL., "Double Blind, Placebo Controlled Trial Of Two Probiotic Straiins In Interleukin 10 Knockout Mice And Mechanistic Link With Cytokine Balance", <u>Gastroenterology</u> , Vol. 122, Nr. 4 Suppl. 1, pages A-389-A390 DDW Meeting Abstract Nr. T962, XP009036733 the whole document	
EXAMINER	Shu	llamith H. Shafer 08/04/2006	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

9188R& PTO-SB08 (Revised for P&G use 10/8/2003) SHEET

1 of 1

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

9188R&

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO COMPLETE IF KNOWN 10/810358 **Application Number** 1244 INFORMATION DISCLOSURE Confirmation Number STATEMENT BY APPLICANT March 26, 2004 Filing Date (use as many meets as necess First Named Inventor Chen et al. Group Art Unit 1616 JUN 3 0 2005 **Examiner Name**

U. S. PATENT DOCUMENTS

Attorney Docket Number

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		U S-2003/0190309A1	10-09-2003	Bell, Boyd & Lloyd	
				LLC	
		US-2005/0106133A1			
		US-	/		
		US-			•

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT Do	CUMENT Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Document	Pages, Columns, Lines Where Relevant Passages or Cited Relevant Figures Appear	T*
				<u></u>			
	<u> </u>						
	<u> </u>						
EXAMINE	^R Shu	lamith H. Shafei	Digitally opined by Shaharath H. St. GN: enrichtstands H. Shakar, cn U.S gen Date: 2006 86 97 88 18 35 -64780'	under , onUSPTO, munAU 1847, emaile shubareth shafer@uspto	DATE CONSIDERED	08/07/2006	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.